Jinwon Life Sciences Begins Animal Testing to Evaluate GLS-1027 Efficacy for Autoimmune Uveitis Treatment

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 27th that it has begun a study to evaluate whether GLS-1027 (international nonproprietary name: Xenuzolak), an immunomodulator that suppresses hyperimmune responses, effectively treats autoimmune uveitis in dogs, an experimental animal.

The company stated, "This study is being conducted with the development of both human and veterinary medicines in mind, led by the veterinary ophthalmology group at Cornell University's College of Veterinary Medicine, and is underway as a randomized, placebo-controlled, double-blind study across multiple institutions," adding, "Since this is a proof-of-concept study to evaluate therapeutic efficacy, the results can also be used to apply for clinical trials of GLS-1027 for the treatment of non-infectious uveitis in humans."

A company official said, "Non-infectious uveitis, an autoimmune disease caused by dysregulated immunity, is a major cause of blindness in humans, horses, and dogs," and added, "Through numerous animal experiments, we have confirmed that the oral immunomodulator GLS-1027 suppresses cytokine-mediated autoimmune diseases."

He continued, "Through the publication of two scientific journal papers, it has been confirmed that GLS-1027 completely suppressed LPS-induced uveitis in rats, an experimental animal, and successfully treated corticosteroid-resistant uveitis in Cavalier King Charles Spaniel dogs."

Park Younggeun, CEO of GeneOne Life Science, said, "Our company has been dedicated to improving treatments for diseases with high morbidity, and through this study, we aim to achieve significant progress in the treatment of inflammatory diseases confirmed by GLS-1027," adding, "GLS-1027 holds important therapeutic potential in both humans and animals."